ethyl (3-phenylisoxazol-5-yl)aminooxoacetate | 85815-05-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl (3-phenylisoxazol-5-yl)aminooxoacetate
• 英文别名: Ethyl 2-oxo-2-[(3-phenyl-5-isoxazolyl)amino]acetate；ethyl 2-oxo-2-[(3-phenyl-1,2-oxazol-5-yl)amino]acetate
• CAS: 85815-05-0
• 化学式: C₁₃H₁₂N₂O₄
• 分子量: 260.249
• InChiKey: ZQFYVNKXRYMEFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  81.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl (3-phenylisoxazol-5-yl)aminooxoacetate 在 platinum(IV) oxide 氢气 作用下， 生成 ethyl 4-hydroxy-6-phenylpyrimidine-2-carboxylate
  参考文献：
  名称：

  Studies on antiallergic agents. I. Phenyl-substituted heterocycles with a 5-tetrazolyl or N-(5-tetrazolyl)carbamoyl group.

  摘要：

  合成了一系列以 5-四唑基或 N-(5-四唑基)氨基甲酰基为酸性分子的苯基取代的吡喃、吡啶和嘧啶。这些化合物在大鼠口服后通过被动皮肤过敏试验（PCA）测试其抗过敏活性。合成的化合物包括发现 N-（5-四唑基）-6-苯基吡啶-2-甲酰胺（53、54 和 55）具有显著的高效力。

  DOI：

  10.1248/cpb.30.4314
• 作为产物：
  描述：

  5-氨基-3-苯基异噁唑 、 草酰氯单乙酯 以 吡啶 为溶剂， 反应 2.0h， 以88%的产率得到ethyl (3-phenylisoxazol-5-yl)aminooxoacetate
  参考文献：
  名称：

  Studies on antiallergic agents. I. Phenyl-substituted heterocycles with a 5-tetrazolyl or N-(5-tetrazolyl)carbamoyl group.

  摘要：

  合成了一系列以 5-四唑基或 N-(5-四唑基)氨基甲酰基为酸性分子的苯基取代的吡喃、吡啶和嘧啶。这些化合物在大鼠口服后通过被动皮肤过敏试验（PCA）测试其抗过敏活性。合成的化合物包括发现 N-（5-四唑基）-6-苯基吡啶-2-甲酰胺（53、54 和 55）具有显著的高效力。

  DOI：

  10.1248/cpb.30.4314

文献信息

• Studies on antiallergic agents. I. Phenyl-substituted heterocycles with a 5-tetrazolyl or N-(5-tetrazolyl)carbamoyl group.
  作者：YASUSHI HONMA、YASUO SEKINE、TOMIKI HASHIYAMA、MIKIO TAKEDA、YASUTOSHI ONO、KEI TSUZURAHARA

  DOI：10.1248/cpb.30.4314

  日期：——

  A series of phenyl-substituted pyrones, pyridines, and pyrimidines bearing a 5-tetrazolyl or N-(5-tetrazolyl) carbamoyl group as an acidic moiety was synthesized. The compounds were tested for antiallergic activity by passive cutaneous anaphylaxis (PCA) assay in rats after oral administration. Among the compounds synthesized. N-(5-tetrazolyl)-6-phenylpyridine-2-carboxamides (53, 54 and 55) were found to display remarkably high potency.

  合成了一系列以 5-四唑基或 N-(5-四唑基)氨基甲酰基为酸性分子的苯基取代的吡喃、吡啶和嘧啶。这些化合物在大鼠口服后通过被动皮肤过敏试验（PCA）测试其抗过敏活性。合成的化合物包括发现 N-（5-四唑基）-6-苯基吡啶-2-甲酰胺（53、54 和 55）具有显著的高效力。
• HONMA, YASUSHI;SEKINE, YASUO;HASHIYAMA, TOMIKI;TAKEDA, MIKIO;ONO, YASUTOS+, CHEM. AND PHARM. BULL., 1982, 30, N 12, 4314-4324
  作者：HONMA, YASUSHI、SEKINE, YASUO、HASHIYAMA, TOMIKI、TAKEDA, MIKIO、ONO, YASUTOS+

  DOI：——

  日期：——
• Metalloprotease inhibitors containing a squaramide moiety
  申请人：Gege Christian

  公开号：US20080221128A1

  公开（公告）日：2008-09-11

  The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• Metalloprotease inhibitors containing a heterocyclic moiety
  申请人：Gege Christian

  公开号：US20080221095A1

  公开（公告）日：2008-09-11

  The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation
  作者：John J. Parlow、Mary W. Burney、Brenda L. Case、Thomas J. Girard、Kerri A. Hall、Ronald R. Hiebsch、Rita M. Huff、Rhonda M. Lachance、Deborah A. Mischke、Stephen R. Rapp、Rhonda S. Woerndle、Michael D. Ennis

  DOI：10.1016/j.bmcl.2009.09.017

  日期：2009.11

  Piperazinyl-glutamate-pyrimidines were prepared with oxygen, nitrogen, and sulfur substitution at the 4-position of the pyrimidine leading to highly potent P2Y(12) antagonists. In particular, 4-substituted piperidine-4-pyrimidines provided compounds with exceptional potency. Pharmacokinetic and physicochemical properties were fine-tuned through modi. cations at the 4-position of the piperidine ring leading to compounds with good human PRP potency, selectivity, clearance and oral bioavailability. (c) 2009 Elsevier Ltd. All rights reserved.